Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG <i>MS</i> study
Tanuja Chitnis, Brenda Banwell, Lauren Krupp, Douglas L. Arnold, Amit Bar‐Or, Wolfgang Brück, Gavin Giovannoni, Benjamin Greenberg, Angelo Ghezzi, Emmanuelle Waubant, Kevin Rostásy, Kumaran Deiva, Peter Huppke, Jerry S. Wolinsky, Ying Zhang, Amin Azmon, Annik K-Laflamme, Rajesh Karan, Jutta Gärtner
Abstract
Background: Reduction in absolute lymphocyte count (ALC) is expected with fingolimod treatment. Objective: To evaluate the effect of fingolimod 0.5 mg versus intramuscular interferon β-1a (30 μg) on ALC and its relationship with infections in paediatric-onset multiple sclerosis (POMS) up to 4 years. Methods: We assessed ALC at baseline, monthly till 3 months, and every 3 months (core phase) and with variable periodicity (extension phase) of Phase 3 PARADIG MS study ( N = 215). Incidence rates (IRs) of infection-related adverse events ( inf AEs)/100 patient-years were analysed by on-study nadir ALC. Results: With fingolimod, ALC rapidly reduced to 29.9%–34.4% of baseline values within 2 weeks and remained stable thereafter; no relevant changes observed with interferon. IRs of inf AEs were 67.6 with fingolimod and 61.8 with interferon; IR ratios with respect to interferon, overall: 1.09, by nadir ALC 0.2–0.4 × 10 9 /L: 1.13 and >0.4 × 10 9 /L: 0.91. Three patients had a single episode of ALC <0.2 × 10 9 /L (core phase). No opportunistic infections were observed and infection risk did not increase during the extension phase. Conclusion: In paediatric patients, the overall incidence of infections was comparable between fingolimod and interferon. No association was observed between nadir ALC and infections in POMS, although sample size may have been too small to rule an association.